Tibial muscular dystrophy

Summary

Tibial muscular dystrophy (MONDO:0010870) is a disease caused by TTN (GenCC Strong), with 5 cohort genes and 43 clinical trials. Top therapeutic interventions include granisetron, lidocaine, and salicylic acid.

At a glance

• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Causal gene: TTN (GenCC Strong)
• Cohort genes: 5
• ClinVar variants: 3,627
• Phenotypes (HPO): 19
• Clinical trials: 43

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000	6	Europe	Validated
Point prevalence	1-5 / 10 000	20	Finland	Validated

Signs & symptoms

Clinical features (HPO)

19 HPO clinical features (Orphanet curated; top 19 by frequency):

HPO ID	Term	Frequency
HP:0003198	Myopathy	Frequent (30-79%)
HP:0003376	Steppage gait	Frequent (30-79%)
HP:0003458	EMG: myopathic abnormalities	Frequent (30-79%)
HP:0003557	Increased variability in muscle fiber diameter	Frequent (30-79%)
HP:0003687	Centrally nucleated skeletal muscle fibers	Frequent (30-79%)
HP:0003805	Rimmed vacuoles	Frequent (30-79%)
HP:0008180	Mildly elevated creatine kinase	Frequent (30-79%)
HP:0009027	Foot dorsiflexor weakness	Frequent (30-79%)
HP:0009049	Peroneal muscle atrophy	Frequent (30-79%)
HP:0009058	Increased muscle lipid content	Frequent (30-79%)
HP:0031374	Ankle weakness	Frequent (30-79%)
HP:0001288	Gait disturbance	Frequent (30-79%)
HP:0002312	Clumsiness	Occasional (5-29%)
HP:0003731	Quadriceps muscle weakness	Occasional (5-29%)
HP:0008994	Proximal muscle weakness in lower limbs	Occasional (5-29%)
HP:0001638	Cardiomyopathy	Excluded (0%)
HP:0002878	Respiratory failure	Excluded (0%)
HP:0009077	Weakness of long finger extensor muscles	Excluded (0%)
HP:0008959	Distal upper limb muscle weakness	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	tibial muscular dystrophy
Mondo ID	MONDO:0010870
OMIM	600334
Orphanet	609
DOID	DOID:0111078
SNOMED CT	698846009
UMLS	C1838244
MedGen	333047
GARD	0013154
Is cancer (heuristic)	no

Also known as: distal myopathy, Udd type · distal titinopathy · Finnish tibial muscular dystrophy · tardive tibial muscular dystrophy · TMD · Udd myopathy

Data availability: 3,627 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › autosomal dominant distal myopathy › tibial muscular dystrophy

Related subtypes (14): myopathy, myofibrillar, 9, with early respiratory failure, distal myopathy, Welander type, myofibrillar myopathy 2, myofibrillar myopathy 3, myofibrillar myopathy 4, Finnish upper limb-onset distal myopathy, distal myopathy with posterior leg and anterior hand involvement, distal myopathy, Tateyama type, adult-onset distal myopathy due to VCP mutation, KLHL9-related early-onset distal myopathy, distal myopathy with vocal cord weakness, TARDBP-related predominantly upper-limb distal myopathy, asymetric thumb-handgrip weakness-distal myopathy, calf-predominant weakness-gastrocnemius medialis atrophy-distal myopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

256 conflicting classifications of pathogenicity, 197 uncertain significance, 70 benign/likely benign, 33 likely benign, 15 likely pathogenic, 15 benign, 9 pathogenic/likely pathogenic, 3 pathogenic, 2 not provided

ClinVar	Variant (HGVS)	Gene	Classification	Review
12652	NM_001267550.2(TTN):c.107780_107790delinsTGAAAGAAAAA (p.Glu35927_Trp35930delinsValLysGluLys)	TTN	Pathogenic	criteria provided, multiple submitters, no conflicts
12654	NM_001267550.2(TTN):c.107840T>A (p.Ile35947Asn)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
132133	NM_001267550.2(TTN):c.95134T>C (p.Cys31712Arg)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
132137	NM_001267550.2(TTN):c.95195C>T (p.Pro31732Leu)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1329193	NM_001267550.2(TTN):c.73939C>T (p.Arg24647Ter)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1508786	NM_001267550.2(TTN):c.80380C>T (p.Gln26794Ter)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
165720	NM_001267550.2(TTN):c.94180delinsTCTAGCAG (p.Pro31394fs)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1686283	NM_001267550.2(TTN):c.65863+1G>A	TTN	Pathogenic	criteria provided, single submitter
179411	NM_001267550.2(TTN):c.49648+2del	TTN	Pathogenic	criteria provided, multiple submitters, no conflicts
179759	NM_001267550.2(TTN):c.81321C>G (p.Tyr27107Ter)	TTN	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1068361	NM_001267550.2(TTN):c.96669G>A (p.Trp32223Ter)	TTN-AS1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
180573	NM_001267550.2(TTN):c.67495C>T (p.Arg22499Ter)	TTN-AS1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1793398	NM_001267550.2(TTN):c.53026_53027del (p.Val17676fs)	LOC126806425	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1066962	NM_001267550.2(TTN):c.56051-1G>A	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1067018	NM_001267550.2(TTN):c.62337_62340del (p.Thr20780fs)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1067630	NM_001267550.2(TTN):c.51449del (p.Pro17150fs)	TTN	Likely pathogenic	criteria provided, single submitter
12653	NM_001267550.2(TTN):c.107867T>C (p.Leu35956Pro)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1285374	NM_001267550.2(TTN):c.23685del (p.Glu7896fs)	TTN	Likely pathogenic	criteria provided, single submitter
1297705	NM_001267550.2(TTN):c.83324dup (p.Arg27776fs)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
130686	NM_001267550.2(TTN):c.98606G>C (p.Arg32869Pro)	TTN	Likely pathogenic	criteria provided, single submitter
1325260	NM_001267550.2(TTN):c.101642C>G (p.Ser33881Ter)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1325263	NM_001267550.2(TTN):c.53728G>T (p.Glu17910Ter)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1326923	NM_001267550.2(TTN):c.2775+1G>T	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1497348	NM_001267550.2(TTN):c.60455_60456del (p.Thr20152fs)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
165975	NM_001267550.2(TTN):c.54638G>A (p.Trp18213Ter)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
167754	NM_001267550.2(TTN):c.104092C>T (p.Arg34698Ter)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1678136	NM_001267550.2(TTN):c.77185A>T (p.Lys25729Ter)	TTN	Likely pathogenic	criteria provided, multiple submitters, no conflicts
166320	NM_001267550.2(TTN):c.4396T>C (p.Phe1466Leu)	LOC101927055	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
130687	NM_001267550.2(TTN):c.100315T>C (p.Trp33439Arg)	LOC126806420	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
191829	NM_001267550.2(TTN):c.100226G>A (p.Cys33409Tyr)	LOC126806420	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 21 · Orphanet: 19 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TTN	Strong	Autosomal dominant	tibial muscular dystrophy	21

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TTN	Orphanet:140922	Titin-related limb-girdle muscular dystrophy R10
TTN	Orphanet:154	Familial isolated dilated cardiomyopathy
TTN	Orphanet:169186	Autosomal recessive centronuclear myopathy
TTN	Orphanet:178464	Hereditary myopathy with early respiratory failure
TTN	Orphanet:289377	Early-onset myopathy with fatal cardiomyopathy
TTN	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
TTN	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
TTN	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
TTN	Orphanet:324604	Classic multiminicore myopathy
TTN	Orphanet:334	Hereditary atrial fibrillation
TTN	Orphanet:466921	Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome
TTN	Orphanet:609	Tibial muscular dystrophy
TTN	Orphanet:707983	Early-onset autosomal recessive TTN-related distal myopathy
ZNF423	Orphanet:2318	Joubert syndrome with oculorenal defect
ZNF423	Orphanet:93591	Infantile nephronophthisis
CORIN	Orphanet:275555	Preeclampsia
LRP4	Orphanet:3152	Sclerosteosis
LRP4	Orphanet:3258	Cenani-Lenz syndrome
LRP4	Orphanet:98913	Postsynaptic congenital myasthenic syndrome

Cohort genes → proteins

5 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TTN	HGNC:12403	ENSG00000155657	Q8WZ42	Titin	gencc,clinvar
ZNF423	HGNC:16762	ENSG00000102935	Q2M1K9	Zinc finger protein 423	clinvar
CORIN	HGNC:19012	ENSG00000145244	Q9Y5Q5	Atrial natriuretic peptide-converting enzyme	clinvar
TTN-AS1	HGNC:44124	ENSG00000237298		TTN antisense RNA 1	clinvar
LRP4	HGNC:6696	ENSG00000134569	O75096	Low-density lipoprotein receptor-related protein 4	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TTN	Titin	Key component in the assembly and functioning of vertebrate striated muscles.
ZNF423	Zinc finger protein 423	Transcription factor that can both act as an activator or a repressor depending on the context.
CORIN	Atrial natriuretic peptide-converting enzyme	Serine-type endopeptidase involved in atrial natriuretic peptide (NPPA) and brain natriuretic peptide (NPPB) processing.
LRP4	Low-density lipoprotein receptor-related protein 4	Mediates SOST-dependent inhibition of bone formation.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	1	7.3×	0.336
Kinase	1	5.5×	0.336
Transcription factor	1	1.6×	0.634
Other/Unknown	2	0.7×	0.877

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TTN	Kinase	yes	2.7.11.1	Prot_kinase_dom, Ig_sub2, Ig_sub
ZNF423	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf
CORIN	Protease	yes		SRCR, Trypsin_dom, LDrepeatLR_classA_rpt
TTN-AS1	Other/Unknown	no
LRP4	Other/Unknown	no		LDLR_classB_rpt, EGF, EGF-like_Ca-bd_dom

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
biceps brachii	2
skeletal muscle tissue of biceps brachii	2
gluteal muscle	1
cartilage tissue	1
cardiac muscle of right atrium	1
heart right ventricle	1
myocardium	1
gastrocnemius	1
hindlimb stylopod muscle	1
right atrium auricular region	1
dorsal motor nucleus of vagus nerve	1
medial globus pallidus	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TTN	223	broad	marker	biceps brachii, gluteal muscle, skeletal muscle tissue of biceps brachii
ZNF423	252	broad	marker	skeletal muscle tissue of biceps brachii, biceps brachii, cartilage tissue
CORIN	176	tissue_specific	marker	cardiac muscle of right atrium, heart right ventricle, myocardium
TTN-AS1	174	ubiquitous	marker	hindlimb stylopod muscle, gastrocnemius, right atrium auricular region
LRP4	242	ubiquitous	marker	ventricular zone, dorsal motor nucleus of vagus nerve, medial globus pallidus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TTN	4,237
ZNF423	1,526
CORIN	1,291
LRP4	1,250
TTN-AS1	0

Structural data

PDB: 3 · AlphaFold-only: 1 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TTN	Q8WZ42	64
ZNF423	Q2M1K9	1
LRP4	O75096	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
CORIN	Q9Y5Q5	70.20

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Physiological factors	1	167.9×	0.026	CORIN
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	1	95.2×	0.026	ZNF423
Striated Muscle Contraction	1	77.2×	0.026	TTN
ECM proteoglycans	1	37.6×	0.040	LRP4
Platelet degranulation	1	22.0×	0.054	TTN
Extracellular matrix organization	1	15.8×	0.062	LRP4

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of presynaptic membrane organization	1	4213.0×	0.009	LRP4
regulation of systemic arterial blood pressure by atrial natriuretic peptide	1	1404.3×	0.009	CORIN
skeletal muscle myosin thick filament assembly	1	1404.3×	0.009	TTN
sarcomerogenesis	1	1404.3×	0.009	TTN
synaptic assembly at neuromuscular junction	1	1404.3×	0.009	LRP4
regulation of renal sodium excretion	1	1053.2×	0.009	CORIN
skeletal muscle thin filament assembly	1	702.2×	0.009	TTN
detection of muscle stretch	1	601.9×	0.009	TTN
postsynaptic membrane assembly	1	601.9×	0.009	LRP4
amyloid-beta clearance by cellular catabolic process	1	526.6×	0.009	LRP4
skeletal muscle acetylcholine-gated channel clustering	1	468.1×	0.009	LRP4
positive regulation of skeletal muscle acetylcholine-gated channel clustering	1	468.1×	0.009	LRP4
cardiac muscle hypertrophy	1	421.3×	0.009	TTN
presynaptic membrane assembly	1	421.3×	0.009	LRP4
generation of neurons	1	383.0×	0.009	LRP4
obsolete protein kinase A signaling	1	351.1×	0.009	TTN
cardiac muscle tissue morphogenesis	1	351.1×	0.009	TTN
enzyme-linked receptor protein signaling pathway	1	324.1×	0.009	LRP4
negative regulation of axonogenesis	1	324.1×	0.009	LRP4
cardiac myofibril assembly	1	324.1×	0.009	TTN
muscle filament sliding	1	263.3×	0.011	TTN
mitotic chromosome condensation	1	247.8×	0.011	TTN
peptide hormone processing	1	234.1×	0.011	CORIN
striated muscle contraction	1	210.7×	0.011	TTN
regulation of cardiac conduction	1	210.7×	0.011	CORIN
proximal/distal pattern formation	1	162.0×	0.013	LRP4
positive regulation of Rac protein signal transduction	1	162.0×	0.013	LRP4
negative regulation of ossification	1	156.0×	0.013	LRP4
cardiac muscle cell development	1	156.0×	0.013	TTN
Rac protein signal transduction	1	140.4×	0.014	LRP4

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5

Druggability breadth: 1 of 5 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TTN	0	0
ZNF423	0	0
CORIN	0	0
TTN-AS1	0	0
LRP4	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TTN	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
TTN	2.7.11.1	non-specific serine/threonine protein kinase

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	TTN
D	Druggable family + AlphaFold only, no drug	1	CORIN
E	Difficult family or no structure, no drug	3	ZNF423, TTN-AS1, LRP4

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TTN	1	—
ZNF423	0	—
CORIN	0	—
TTN-AS1	0	—
LRP4	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 43.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	40
PHASE4	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07401745	PHASE4	ACTIVE_NOT_RECRUITING	Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders
NCT03522207	PHASE4	TERMINATED	Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient
NCT01659372	PHASE1	UNKNOWN	Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
NCT05676827	Not specified	ENROLLING_BY_INVITATION	Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain
NCT06428136	Not specified	ACTIVE_NOT_RECRUITING	Comparative Effects of Clamshell Technique With EMS vs CTin Iliotibial Band Tightness for Pain and Function
NCT06562556	Not specified	NOT_YET_RECRUITING	Impact of Breather Device on Ventilatory Effort in Patient With MTMD
NCT06677216	Not specified	ENROLLING_BY_INVITATION	Botulinum Toxin in the Management of Temporo-mandibular Related Myalgia: a Prospective Study
NCT06752200	Not specified	NOT_YET_RECRUITING	AMOUNT OF INTRAORAL OCCLUSAL ADJUSTMENTS IN OCCLUSAL SPLINTS FABRICATED USING FULLY DIGITAL VERSUS COMBINED DIGITAL WORKFLOW IN TMD PATIENTS
NCT06781320	Not specified	NOT_YET_RECRUITING	Digital Occlusal Analysis and Enamel Wear Assessment in Temporomandibular Disorder Patients Treated with Fully Digital Versus Conventional Stabilization Splints
NCT06948162	Not specified	RECRUITING	Exploration of the Utility of Dental-dedicated MRI for Dentistry
NCT06994156	Not specified	ACTIVE_NOT_RECRUITING	Diagnostic and Prognostic Salivary Biomarkers in Chronic Muscle Pain
NCT07115797	Not specified	NOT_YET_RECRUITING	ARS vs ARS With Arthrocentesis and PRP Injection in DDWR
NCT07226505	Not specified	NOT_YET_RECRUITING	Effects of Core Strengthening Exercises for Treating TMD
NCT07288411	Not specified	NOT_YET_RECRUITING	Effects of Vagus Nerve Stimulation on Temporomandibular Disorders.
NCT07297459	Not specified	ENROLLING_BY_INVITATION	Arthroscopic Anterior Release Versus Discectomy as Treatments for Temporomandibular Joint Disc Displacement With Reduction
NCT07304557	Not specified	RECRUITING	Effects Exercises in Temporomandibular Joint Disorders on Pain, Joint and Tongue Functions
NCT07351812	Not specified	RECRUITING	Two Treatment Modalities for Myogenous Temporomandibular Disorders
NCT07474662	Not specified	RECRUITING	Comparing the Effectiveness of Online vs. Face-to-face Physiotherapy for Treating Temporomandibular Disorders
NCT07584642	Not specified	NOT_YET_RECRUITING	Efficacy and Safety of HA35 Gel Nighttime Occlusive Application for TMD Pain
NCT07600203	Not specified	RECRUITING	A Double-blind, Placebo-controlled Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ
NCT07614932	Not specified	NOT_YET_RECRUITING	Arthroscopic Lysis and Lavage With and Without Intra-articular Injection of Hyaluronic Acid in Patients With DDwoR in TMJ
NCT02427113	Not specified	UNKNOWN	What Are the Effects of Music on Temporomandibular Disorder Symptoms?
NCT02946645	Not specified	COMPLETED	Efficiency of Neuromuscular Bite vs Physiotherapy in TMD Patients
NCT03398486	Not specified	COMPLETED	The Effectiveness of Kinesiotaping and Inactivation of Trigger Points in Chronic Myofascial Pain of TMD
NCT04241562	Not specified	COMPLETED	Validation of a Novel Cortical Biomarker Signature for Pain
NCT04298554	Not specified	COMPLETED	Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region
NCT04326608	Not specified	UNKNOWN	Psycho-social Aspects After a Physiotherapy Intervention in Chronic TMD Pain
NCT04409067	Not specified	COMPLETED	Masticatory Muscle Activity in Patients With Pain-related Temporomandibular Disorders
NCT04543981	Not specified	UNKNOWN	Prevalence of the Signs and Symptoms of TMD in Adolescents
NCT04618445	Not specified	UNKNOWN	Prevalence of Temporomandibular Joint Disorders Among Egyptian University Undergraduate Students
NCT05003349	Not specified	COMPLETED	Pain Neuroscience Education, Motor Imagery and Action Observation in Patients With Chronic Temporomandibular Disorders.
NCT05288647	Not specified	COMPLETED	Computer Guided Versus Conventional TMJ Injection
NCT05302466	Not specified	COMPLETED	Additive Effects of Dental Bite Pads During Gymnastic Exercises for the Relief of Chronic Non-specific Neck Pain in Working Women and Men at a VDU Workplace
NCT05522114	Not specified	COMPLETED	Accuracy of Patient Specific Guide for TMJ Injection
NCT05620758	Not specified	UNKNOWN	Laser Therapy and Temporomandibular Disorders
NCT05660343	Not specified	COMPLETED	Ozonated Olive Oil and Low-Level Laser Therapy in TMD Treatment
NCT05862870	Not specified	COMPLETED	TMD Online Program for Pain Management
NCT05955222	Not specified	COMPLETED	Clinical Performance of CAD/CAM Splint Materials
NCT06087432	Not specified	COMPLETED	Is PNF Application Effective on Temporomandibular Dysfunction
NCT06339736	Not specified	COMPLETED	Treatment Outcomes in Patients With Muscular Temporo-mandibular Joint Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GRANISETRON	4	1
LIDOCAINE	4	1
SALICYLIC ACID	4	1
TRAZODONE	4	1
CHEMBL399538	0	1